Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia
Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia
Study will recruit pregnant or postpartum women presenting to Groote Schuur Hospital with
 cardiovascular disease in 20 consecutive patients and will insert an implantable ECG
 monitoring device. The patient will then be followed up over a duration of two year and will
 be monitored for arrhythmia and mortality.
Background

 Worldwide, the numbers of women who have a pre-existing cardiovascular disease or develop
 cardiac problems during pregnancy are increasing and, due to the lack of evidenced-based
 data, this provides challenges for the treating physician. Cardiovascular disease in
 pregnancy is a complex topic as women can present either pre- or postpartum, due to a
 pre-existing heart disease such as e.g. operated or unoperated congenital heart disease,
 valvular heart disease, and chronic hypertension or familial dilated cardiomyopathy. On the
 other hand, there are diseases which are directly associated with pregnancy such as
 hypertensive disorders of pregnancy and peripartum cardiomyopathy (PPCM). Women often present
 with symptoms and signs of cardiovascular disease such as palpitations and shortness of
 breath, or even directly in acute heart failure. There is, in particular, a paucity of data
 from developing countries of this unique disease pattern and presentations. Pregnancy poses a
 physiological stress test as cardiac output increases by 30-50% close to term. Further
 haemodynamic stress occurs during labour and many of the effects of pregnancy on
 cardiovascular disease (CVD) persist for several months after delivery.

 Awareness of the different cardiovascular diseases that can occur in pregnancy or postpartum
 has received limited attention and the main focus has been on hypertension and preeclampsia.
 The global impact of elevated blood pressure (BP)/hypertension, in general, is profound, as
 it is responsible for more deaths worldwide than any other cardiovascular risk factor,
 including tobacco use, obesity and lipid disorders (Vos, Sliwa et al. Lancet 2012; Gersh &
 Sliwa, Eur Heart J 2010).

 Beyond the higher income countries, 80% of worldwide CVD-related deaths now occur in low- and
 middle-income countries (LMICs) (Sliwa, Stewart Circulation 2011; Abergunde, Mathers et al,
 Lancet, 2007). In LMICs, morbid and fatal CVD-related events typically occur at a younger age
 and affect more women (commonly in pregnancy), thereby exerting a more profound impact on the
 family unit and the workforce. The recently published Global Burden of Disease Study which
 reports on Years Lived with Disabilities (YLDs) for 1160 sequelae of 289 diseases and
 injuries does not report on the prevalence of CVD pre- and postpartum as an entity. However,
 globally, it is estimated that CVD and, in particular, hypertensive disorders of pregnancy,
 complicate 2-8% of pregnancies contributing, to a major extent, to maternal mortality
 worldwide (Sliwa, Cardiovascular Research, in press 2014). Chronic hypertension is now
 prevalent in 3% of women falling pregnant in the US (Seely and Ecker, N Engl J Med, 2011) and
 will also influence the prevalence of acute coronary syndromes (ACS) in pregnancy.

 The recent confidential inquiry into maternal death in South Africa reported that of the 4867
 deaths reported over 2 years, 14% were due to hypertensive disorders, with another 8.8% due
 to medical and surgical conditions (www.hst.org/za/saving-mothers-2008-2010. This makes
 cardiac disease in pregnancy a key focus area, with the aim of reducing morbidity and
 mortality, not only by the South African Department of Health but also by the World Health
 Organization and World Heart Federation.

 We have recently carried out a single-centre prospective study on women presenting with CVD
 in pregnancy at Groote Schuur Hospital, University of Cape Town, South Africa (manuscript
 submitted). This study investigates an appropriate referral algorithm and reports on disease
 presentation (n=226) and outcome of those patients, with significant disease warranting
 follow-up at a tertiary care (n=152). Of the 152 women that were asked to come back for
 follow-up, the CDMC 122 (80.2%) presented prepartum. The most common diagnoses where
 congenital heart disease, valvular heart disease, cardiomyopathy and other diagnoses such as
 e.g. Wolf-Parkinson-White, atrial fibrillation, arrhythmogenic right ventricular
 cardiomyopathy.

 Management of these patients is complex as palpitations in pregnancy are common due to
 increased sympathetic tone. It is important to distinguish palpitations secondary to benign
 tachycardias, such as sinus tachycardia, from more important arrhythmias, such as
 supraventricular or ventricular tachyarrythmias. Supraventricular arrhythmias are known to
 increase in pregnancy, presumably because of an increase in sympathetic tone. Ventricular
 arrhythmias secondary to some long QT syndrome subtypes are known to increase in the
 peripartum period. On the other hand, undiagnosed complex arrhythmia can have serious
 consequences for the mother and fetus, including stroke and death. Most CV drugs are
 contraindicated in pregnancy or have a FDA class C and D classification - e.g. beta-blockers
 (C & D), soltalol (C) and amiodarone (D). The treating physician therefore needs to document
 the exact nature of the arrhythmia-causing symptoms, such as palpitations, dizziness and
 syncope, prior to making a decision on pharmacological or device management. As 24-hour
 holters have a low diagnostic yield, the use of an ECG loop recorder ( REVEAL) could
 potentially influence management.

 Interestingly, we have used the REVEAL XT in 2 pregnant women with newly diagnosed
 arrrythmogenic right ventricular cardiomyopathy and a strong family history of sudden cardiac
 death. Sinus tachycardia was present and correlated with the symptoms of palpitations. As
 only supraventricular tachycardia was detected, patients could be managed conservatively and
 had good maternal and fetal outcome. On the other hand, 2 other women presenting with
 palpitations and dizziness in pregnancy were subsequently diagnosed with cardiac sarcoidosis,
 a serious condition associated with sudden cardiac death.

 1. Objectives:

 1.1. To investigate the use of a small ECG loop recorder (REVEAL devices) in pregnant
 women, with or without structural heart disease, in whom supra/ventricular
 tachyarrhythmias and bradyarrythmias are suspected.

 2.1. To investigate if the REVEAL device will change management compared to a single 24
 hour holter done at presentation.

 Our research question is based on preliminary information, having used the REVEAL XT in
 2 pregnant women with newly diagnosed arrhythmogenic right ventricular cardiomyopathy
 and a strong family history of sudden cardiac death. As only supraventricular sinus
 tachycardia was detected, patients could be managed conservatively and had good maternal
 and fetal outcome. On the other hand, 2 other women presenting with palpitations and
 dizziness in pregnancy were subsequently diagnosed with cardiac sarcoidosis, a serious
 condition associated with sudden cardiac death. A REVEAL device should have been used to
 guide the physician in management.

 2. Patient population

 The patients will be recruited via a single-centre, prospective study of women with
 cardiovascular disease presenting pre- or postpartum, attending Groote Schuur Hospital.
 Since 1 July 2010, these patients have been seen at a weekly clinic, jointly run by
 cardiologists and obstetricians, under the leadership of Prof. Karen Sliwa and Prof John
 Anthony. We see about 100 new patients presenting with cardiovascular disease in
 pregnancy per annum. About 200 newly diagnosed pregnant women with documented or
 suspected cardiovascular disease will be screened for the indication to insert a REVEAL
 device. Those patients will be part of an ongoing registry entitled: Registry of newly
 diagnosed cases with cardiac disease in maternity-Phase II ( CDM-2).

 Device:

 The REVEAL device has the size of a larger USB stick and can be inserted under local
 anaesthetic under sterile conditions as e.g. a minor procedure room. It is inserted
 under the skin and there are no wires connecting it e.g. to the cardiac chambers or any
 vessels. The device can record the cardiac rhythm for the period to up to one year. The
 REVEAL is routinely ised in South Africa for more than 10 years.

 3. Study design and treatment groups

 A single-centre, observational outcome study investigating peripartum women presenting
 with symptoms and signs of arrhythmia.

 We aim to recruit 20 consecutive women with an indication for the REVEAL, from a
 population of about 200 pregnant women with documented or suspected cardiovascular
 disease as part of the ongoing cardiovascular disease in pregnancy registry.

 Human Ethics Committee approval has been obtained for the overall prospective outcome
 study on cardiovascular disease in pregnancy (HEC REF: 173/2010)

 Estimate study duration: 2 years Estimate study start date: June 2014 Estimate study end
 date: May 2016

 4. Endpoints

 Our prospective study will answer the questions whether REVEAL devices:

 4.1. Are acceptable as a diagnostic tool in pregnant women. This will be assessed by
 documentation of a number of women presenting with an indication to have the REVEAL
 inserted (based on standard criteria) and a number of women accepting to have the
 device. We see about 100 new patients presenting with cardiovascular disease in
 pregnancy per annum.

 4.2. Detect arrhythmias in pregnancy and can guide the cardiologist and obstetrician in
 appropriate management, ranging from assurance, to medical therapy, to device therapy or
 termination of pregnancy.

 4.3. Change the management of the condition compared to a single ECG performed at the
 day of offering insertion of the REVEAL device.

 5. Measurable outputs and Publication Plan

 Presentation of data In the past decade I have been invited annually to present my research
 in the form of invited lectures at the following meetings: Congress of the Heart Failure
 Association of the ESC; European Cardiac Society of Cardiology, World Congress of Cardiology,
 South African Heart Failure Society, Pan African Cardiac Society. The data obtained from the
 study will be presented at those meetings.

 Publication of Original Data The data will be published as part of the overall cardiac
 disease in pregnancy registry and as a separate paper.
Inclusion Criteria:

 -  Pregnant or postpartum women presenting to Groote Schuur Hospital with cardiovascular
 disease.

 Exclusion Criteria:

 -Individuals with structural heart disease.